- Home
- PED vs BOLD Comparison
PED vs BOLD Comparison
Compare PED & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PED
- BOLD
- Stock Information
- Founded
- PED N/A
- BOLD 2018
- Country
- PED United States
- BOLD United States
- Employees
- PED N/A
- BOLD N/A
- Industry
- PED Oil & Gas Production
- BOLD
- Sector
- PED Energy
- BOLD
- Exchange
- PED Nasdaq
- BOLD Nasdaq
- Market Cap
- PED 48.8M
- BOLD 24.4M
- IPO Year
- PED N/A
- BOLD 2024
- Fundamental
- Price
- PED $0.64
- BOLD $1.12
- Analyst Decision
- PED Strong Buy
- BOLD Buy
- Analyst Count
- PED 2
- BOLD 3
- Target Price
- PED $1.63
- BOLD $4.00
- AVG Volume (30 Days)
- PED 567.8K
- BOLD 279.9K
- Earning Date
- PED 08-13-2025
- BOLD 08-11-2025
- Dividend Yield
- PED N/A
- BOLD N/A
- EPS Growth
- PED 2248.88
- BOLD N/A
- EPS
- PED 0.19
- BOLD N/A
- Revenue
- PED $40,173,000.00
- BOLD N/A
- Revenue This Year
- PED N/A
- BOLD N/A
- Revenue Next Year
- PED $5.99
- BOLD N/A
- P/E Ratio
- PED $3.26
- BOLD N/A
- Revenue Growth
- PED 30.70
- BOLD N/A
- 52 Week Low
- PED $0.47
- BOLD $1.00
- 52 Week High
- PED $1.10
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- PED 47.87
- BOLD N/A
- Support Level
- PED $0.61
- BOLD N/A
- Resistance Level
- PED $0.67
- BOLD N/A
- Average True Range (ATR)
- PED 0.03
- BOLD 0.00
- MACD
- PED -0.00
- BOLD 0.00
- Stochastic Oscillator
- PED 61.81
- BOLD 0.00
About PED Pedevco Corp.
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.